Dehydroabietic acid PROTACs as well as preparation method and application thereof
By developing dehydrorosinic acid PROTACs, the structure of E3 ubiquitin ligase ligand and linking chains is used to achieve targeted degradation of liver fibrosis pathogenic proteins, solving the poor effect of traditional drugs in the treatment of liver fibrosis. The problem has improved the efficacy and inhibition of the drug, adapted to the mutation problem of target proteins.
Patent Information
- Application Number
- CN202410721938.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-05
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-06-05
AI Technical Summary
When existing drugs treat diseases such as liver fibrosis, it is difficult to effectively degrade pathogenic proteins, resulting in poor treatment effects. Traditional small-molecule drugs have high requirements for target protein binding sites and poor drug resistance.
Dehydrogenated rosin acid PROTACs have a structure including E3 ubiquitin ligase ligand and fat chain or PEG chain linker to exert anti-hepatic fibrosis activity through a targeted degradation mechanism, and to achieve degradation of target proteins in any corner location.
Through targeted degradation of the pathogenic protein of liver fibrosis, the efficacy of anti-hepatic fibrosis is significantly improved, the drug concentration requirements are reduced, the inhibition is enhanced, the mutation problem of target proteins is adapted to the treatment effect.
Smart Images

Figure CN118955468A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of organic synthesis, and specifically relates to dehydroabietic acid PROTACs and a preparation method and application thereof. Background Art
[0002] Proteolysis-Targeting Chimeras (PROTACs) are a new type of drug with good prospects. Its structure is similar to a dumbbell and is mainly composed of three parts, including E3 ligase ligand (E3 ligand), target protein ligand (POI ligand) and a linker connecting the two. One end of the PROTACs molecule binds to the target protein and the other end binds to the E3 ubiquitin ligase. The E3 ubiquitin ligase can "stick" a small protein called ubiquitin to the target protein, marking the target protein as a defective or damaged protein, and then using the cell's intrinsic proteolytic enzyme (i.e., 26S proteasome) to specifically recognize and degrade the marked target protein. E3 ligands can recruit E3 ligases, and POI ligands can recognize and bind to target proteins. Therefore, PROTACs molecules will form a POI:PROTAC:E3 ligase ternary complex in cells. In the patient's body, the POI ligand of PROTACs binds to the target protein, and the E3 ligand binds to the substrate binding region of the E3 ubiquitin ligase in the cell. The target protein can be "pulled" to the side of the E3 ubiquitin ligase through the Linker, so that the ubiquitin-proteasome (UPS) system can degrade the target protein. PROTACs molecules do not need to be highly embedded in the highly active area of the target, but only need to have a short-term bonding effect with its surface, that is, only some special intermolecular forces and other low-bond energy weak binding effects can be used to achieve the degradation of the target molecule. At present, because the unique driving model of protein degradation mediated by PROTACs has huge therapeutic potential, this technology is currently mainly used in drug development, and some PROTACs have been clinically tested.
[0003] PROTAC drugs have many advantages over traditional small molecule drugs, as follows:
[0004] (1) PROTAC drug design is not limited by Lipinski's five-fold rule;
[0005] (2) The pharmacological effects of traditional small molecules rely on the occupation of key sites of the target protein (i.e. occupancy-driven). The principle is to bind to the active site of the enzyme or receptor to exert its effect, and the efficacy of the project is poor. Traditional drugs need to maintain a certain drug concentration in the body, and have high requirements for small molecule binding sites. However, PROTACs can capture the target protein through any corner position. Its pharmacological mechanism is to activate potential targets, thereby degrading the target protein and achieving pharmacodynamic effects. Data show that the drug effect does not require very high drug concentrations to achieve, the requirements for binding sites are relatively low, and the efficacy is better;
[0006] (3) About 50% of the proteins in the human body are found to be related to human diseases, such as cancer. However, only about 20% of these proteins can be bound by traditional small molecules, while PROTACs can theoretically bind to any part of the protein;
[0007] (4) PROTAC is comparable to traditional small molecules, and the problem of drug resistance can be ignored. In theory, PROTAC can better tolerate the mutation problem of the target protein;
[0008] (5) PROTACs are more durable and have stronger inhibitory effects than traditional drug molecules; Summary of the invention
[0009] The object of the present invention is to provide a dehydroabietic acid PROTACs.
[0010] Another object of the present invention is to provide a method for preparing the above-mentioned dehydroabietic acid PROTACs.
[0011] Another object of the present invention is to provide the application of the above-mentioned dehydroabietic acid PROTACs.
[0012] The technical solution of the present invention is as follows:
[0013] A dehydroabietic acid PROTACs, characterized in that: its structural formula is
[0014] in,
[0015] E3 ligase is lenalidomide or pomalidomide,
[0016] Linker is a fat chain or a PEG chain. The fat chain is -NH-(CH2)-NH-(CH2)n1-CH2-CH2-NH-CO- or -NH-(CH2)n2-CH2-NH-CO-. The PEG chain is -(O-CH2-CH2)n3-CH2 CO-COOH. n1 is a natural number from 2 to 7, n2 is a natural number from 1 to 7, and n3 is a natural number from 1 to 3.
[0017] In a preferred embodiment of the present invention, its structural formula is selected from at least one of the following:
[0018]
[0019]
[0020]
[0021] The preparation method of the above-mentioned dehydroabietic acid PROTACs has a reaction route as follows:
[0022] or
[0023]
[0024] or
[0025]
[0026] or
[0027]
[0028] Use of the above-mentioned dehydroabietic acid PROTACs or pharmacologically or physiologically acceptable salts thereof in the preparation of a cancer treatment composition.
[0029] In a preferred embodiment of the present invention, the cancer includes breast cancer, uterine cancer and liver cancer.
[0030] A cancer treatment composition, the active ingredient of which includes the above-mentioned dehydroabietic acid PROTACs or a pharmacologically or physiologically acceptable salt thereof.
[0031] In a preferred embodiment of the present invention, the cancer includes breast cancer, uterine cancer and liver cancer.
[0032] The beneficial effect of the present invention is that the present invention can exert the activity of resisting liver fibrosis by targeted degradation of pathogenic proteins causing liver fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 This is a distribution diagram of the differentially expressed proteins in cells in Example 5 of the present invention.
[0034] Figure 2 The top 20 downregulated differentially expressed proteins of T-PROTAC VS T in Example 5 of the present invention are shown.
[0035] Figure 3 The top 20 downregulated differentially expressed proteins of T-PROTAC VS con in Example 5 of the present invention are shown.
[0036] Figure 4 The top 20 down-regulated differentially expressed proteins of T VS con in Example 5 of the present invention are shown.
[0037] Figure 5 The docking and binding site prediction between TMBIM6 and dehydroabietic acid molecules in Example 6 of the present invention are shown.
[0038] Figure 6 The results show the effects of dehydroabietic acid and T15 on the expression of TMBIM6 protein in Example 7 of the present invention.
[0039] Figure 7 The quantitative analysis of the expression of TMBIM6 protein by dehydroabietic acid and T15 in Example 7 of the present invention is shown. DETAILED DESCRIPTION
[0040] The technical solution of the present invention is further illustrated and described below through specific implementation modes in combination with the accompanying drawings.
[0041] The following dehydroabietic acid PROTACs prepared in Examples 1 to 3 are listed as follows:
[0042]
[0043]
[0044]
[0045]
[0046] Example 1
[0047] (1) Preparation of intermediates s1-s12 (preparation of E3 ligand)
[0048] A. The structural formula of intermediate s1(n=1) / s3(n=2) / s5(n=3) / s7(n=4) / s9(n=5) / s11(n=6) is The specific synthesis method is as follows:
[0049] Boc-β-alanine (1g, 5.2mmol), DIPEA (1.81mL, 10.4mmol) were dissolved in 1mL dry DMF solution, stirred at room temperature for 5min, HATU (1.6g, 4.16mmol) was added, and the reaction was monitored by TLC for about 0.5h, and then lenalidomide (876mg, 3.38mmol) was added and stirred at room temperature. TLC tracked the reaction, and the reaction was completed in about 12h. Crushed ice was added to the reaction solution to quench the reaction, and ethyl acetate was extracted 3 times. The organic layers were combined, washed with saturated ammonium chloride solution and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and PTLC (dichloromethane: methanol = 20: 1) was used to obtain intermediate s1 (white solid, 1.3g, 90%).
[0050] Boc-4-aminobutyric acid (1g, 4.9mmol), DIPEA (1.71mL, 9.8mmol) were dissolved in 1mL dry DMF solution, stirred at room temperature for 5min, HATU (1.49g, 3.92mmol) was added, and the reaction was monitored by TLC for about 0.5h, and then lenalidomide (826mg, 3.2mmol) was added and stirred at room temperature. TLC tracked the reaction, and the reaction was complete in about 12h. Crushed ice was added to the reaction solution to quench the reaction, and ethyl acetate was extracted 3 times. The organic layers were combined, washed with saturated ammonium chloride solution and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and PTLC (dichloromethane: methanol = 20: 1) was used to obtain intermediate s3 (white solid, 1.28g, 90%).
[0051] Boc-5-aminopentanoic acid (1g, 4.6mmol), DIPEA (1.6mL, 9.2mmol) were dissolved in 1mL dry DMF solution, stirred at room temperature for 5min, HATU (1.4g, 3.68mmol) was added, and the reaction was monitored by TLC for about 0.5h, and then lenalidomide (775mg, 2.99mmol) was added and stirred at room temperature. TLC followed the reaction and the reaction was complete in about 12h. Crushed ice was added to the reaction solution to quench the reaction, and ethyl acetate was extracted 3 times. The organic layers were combined, washed with saturated ammonium chloride solution and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and PTLC (dichloromethane: methanol = 20: 1) was used to obtain intermediate s5 (white solid, 1.25g, 91%).
[0052] Boc-6-aminohexanoic acid (1g, 4.3mmol), DIPEA (1.5mL, 8.6mmol) were dissolved in 1mL dry DMF solution, stirred at room temperature for 5min, HATU (1.31g, 3.44mmol) was added, and the reaction was monitored by TLC for about 0.5h, and then lenalidomide (725mg, 2.8mmol) was added and stirred at room temperature. TLC followed the reaction and the reaction was complete in about 12h. Crushed ice was added to the reaction solution to quench the reaction, and ethyl acetate was extracted 3 times. The organic layers were combined, washed with saturated ammonium chloride solution and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and PTLC (dichloromethane: methanol = 20: 1) was used to obtain intermediate s7 (white solid, 1.2g, 92%).
[0053] Boc-7-aminoheptanoic acid (1g, 4.1mmol), DIPEA (1.43mL, 8.2mmol) were dissolved in 1mL dry DMF solution, stirred at room temperature for 5min, HATU (1.25g, 3.28mmol) was added, and the reaction was monitored by TLC for about 0.5h, and then lenalidomide (691mg, 3.38mmol) was added and stirred at room temperature. TLC tracked the reaction, and the reaction was complete in about 12h. Crushed ice was added to the reaction solution to quench the reaction, and ethyl acetate was extracted 3 times. The organic layers were combined, washed with saturated ammonium chloride solution and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and PTLC (dichloromethane: methanol = 20: 1) was used to obtain intermediate s9 (white solid, 1.53g, 93%).
[0054] Boc-8-aminocaprylic acid (1g, 3.8mmol), DIPEA (1.3mL, 7.6mmol) were dissolved in 1mL dry DMF solution, stirred at room temperature for 5min, HATU (1.16g, 3.04mmol) was added, and the reaction was monitored by TLC for about 0.5h, and then lenalidomide (640mg, 2.47mmol) was added and stirred at room temperature. TLC tracked the reaction, and the reaction was completed in about 12h. Crushed ice was added to the reaction solution to quench the reaction, and ethyl acetate was extracted 3 times. The organic layers were combined, washed with saturated ammonium chloride solution and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and PTLC (dichloromethane: methanol = 20: 1) was used to obtain intermediate s11 (white solid, 1.11g, 90%).
[0055] B. The structural formula of intermediate s2(n=1) / s4(n=2) / s6(n=3) / s8(n=4) / s10(n=5) / s12(n=6) is The specific synthesis method is as follows:
[0056] The intermediate s1 (1 g, 2.25 mmol) was dissolved in a mixed solution (10 mL) of DCM / MeOH (V:V=3:1), and TFA (3 mL) was added dropwise under an ice bath. After the addition was completed, the mixture was slowly moved to room temperature for reaction. The reaction was monitored by TLC. The reaction was completed in about 12 hours. After the reaction stopped, the solvent was removed by concentration under reduced pressure to obtain the intermediate s2 (white solid, 713 mg, 96.0%), which was directly used in the next step without purification.
[0057] The intermediate s3 (1 g, 2.25 mmol) was dissolved in a mixed solution (10 mL) of DCM / MeOH (V:V=3:1), and TFA (3 mL) was added dropwise under an ice bath. After the addition was completed, the mixture was slowly moved to room temperature for reaction. The reaction was monitored by TLC. The reaction was completed in about 12 hours. After the reaction stopped, the solvent was removed by concentration under reduced pressure to obtain the intermediate s4 (white solid, 675 mg, 91%), which was directly used in the next step without purification.
[0058] The intermediate s5 (1 g, 2.25 mmol) was dissolved in a mixed solution (10 mL) of DCM / MeOH (V:V=3:1), and TFA (3 mL) was added dropwise under an ice bath. After the addition was completed, the mixture was slowly moved to room temperature for reaction. The reaction was monitored by TLC. The reaction was completed in about 12 hours. After the reaction stopped, the solvent was removed by concentration under reduced pressure to obtain the intermediate s6 (white solid, 705 mg, 95.0%), which was directly used in the next step without purification.
[0059] The intermediate s7 (1 g, 2.25 mmol) was dissolved in a mixed solution (10 mL) of DCM / MeOH (V:V=3:1), and TFA (3 mL) was added dropwise under an ice bath. After the addition was completed, the mixture was slowly moved to room temperature for reaction. The reaction was monitored by TLC. The reaction was completed in about 12 hours. After the reaction stopped, the solvent was removed by concentration under reduced pressure to obtain the intermediate s8 (white solid, 690 mg, 93.0%), which was directly used in the next step without purification.
[0060] The intermediate s9 (1 g, 2.25 mmol) was dissolved in a mixed solution (10 mL) of DCM / MeOH (V:V=3:1), and TFA (3 mL) was added dropwise under an ice bath. After the addition was completed, the mixture was slowly moved to room temperature for reaction. The reaction was monitored by TLC. The reaction was completed in about 12 hours. After the reaction stopped, the solvent was removed by concentration under reduced pressure to obtain the intermediate s10 (white solid, 668 mg, 90.0%), which was directly used in the next step without purification.
[0061] The intermediate s11 (1 g, 2.25 mmol) was dissolved in a mixed solution (10 mL) of DCM / MeOH (V:V=3:1), and TFA (3 mL) was added dropwise under an ice bath. After the addition was completed, the mixture was slowly moved to room temperature for reaction. The reaction was monitored by TLC. The reaction was completed in about 12 hours. After the reaction stopped, the solvent was removed by concentration under reduced pressure to obtain the intermediate s12 (white solid, 683 mg, 92.0%), which was directly used in the next step without purification.
[0062] (2) Preparation of intermediate a1
[0063] Dehydroabietic acid (300 mg, 1 mmol) was added to anhydrous dichloroethane (15 mL), stirred at 0°C, and oxalyl chloride (254 mg, 2 mmol) was added dropwise to the mixture, and stirred at room temperature for 6 h. After the reaction, the solvent and excess oxalyl chloride were evaporated under reduced pressure to obtain intermediate a1 (reddish brown solid, 375 mg, yield 90%).
[0064] (3) Preparation of final product T1-6
[0065] The intermediate a1 (1 eq), s2 / s4 / s6 / s8 / s10 / s12 (1.96 eq), EDCl (1.96 eq), and DMAP (1 eq) were dissolved in DCM in sequence. The reaction was stirred at room temperature for 5 to 8 h, extracted with DCM, and the organic phase was washed with 5% NaHCO3 solution and saturated sodium chloride, and dried over anhydrous Na2SO4. The solid was removed by filtration, and the solvent was evaporated under reduced pressure to obtain a crude product, which was then purified by column chromatography (PE-EA = 10:1 to 1:1, v / v) to obtain the final product T1 / 2 / 3 / 4 / 5 / 6, whose NMR data are as follows:
[0066] Final product T1 (white powder, 36.7%): ESI-MS m / z 635.32 [M+Na]+. 1H NMR (500 MHz, Chloroform-d) δ9.47 (s, 1H), 9.41 (d, J=20.7 Hz, 1H), 7.82 (dd, J=15.1, 7.9 Hz, 1H), 7.56 (d, J=7.5 Hz, 1H), 7.35 (td, J=7.8, 3.1 Hz, 1H), 7.11 (dd, J=8.4, 1.5 Hz, 1H),6.97(dt,J=8.3,2.2Hz,1H),6.95–6.82(m,1H),6.77(dd,J=18.2,2.0Hz,1H),5.0 3(dq,J=12.5,6.1,5.6Hz,1H),4.32(s,2H),3.54(dt,J=11.2,6.2Hz,2H),2.82–2.71(m ,2H),2.64(d,J=7.3Hz,2H),2.25(d,J=12.4Hz,1H),2.21–2.11(m,1H),2.10–2.05(m, 1H),2.02–1.94(m,1H),1.91–1.82(m,1H),1.81–1.71(m,2H),1.64–1.60(m,1H),1.48 (d,J=10.5Hz,1H),1.39(dq,J=10.3,6.6,5.4Hz,2H),1.21(d,J=2.5Hz,3H),1.19(s,3 H),1.18(s,3H),1.14(dd,J=8.7,3.2Hz,3H),0.95–0.90(m,1H),0.87–0.79(m,2H).13C NMR (126MHz, CDCl3) δ180.21,179.73,172.44,170.89,169.31,147.09,14 5.05,141.95,135.86,133.44,132.06,130.30,129.15,126.97,124.13,12 3.72,123.67,61.26,47.30,45.49,44.16,37.06,34.38,30.22,29.25,25. 89,25.39,24.08,21.15,19.96,19.24,18.57,16.54,15.97,14.99,14.29.
[0067] Final product T2 (white powder, 32.1%): ESI-MS m / z 649.34 [M+Na]+.1H NMR(500MHz,Chloroform-d)δ8.36(s,1H),7.85(t,J=8.6Hz,1H),7.72–7.61(m,1H),7.45(dd,J=14.5,6.9Hz,1H),7.37–7.27(m,1H),7.18–7 .11(m,1H),7.06–6.94(m,1H),6.88–6.77(m,1H),6.08(s,1H),5.41–5 .09(m,2H),4.47(d,J=14.6Hz,2H),4.26(t,J=5.6Hz,1H),3.83(d,J=16 .1Hz,2H),3.65–3.57(m,2H),3.28–3.19(m,1H),2.84–2.79(m,2H),2. 68(s,1H),2.45(s,2H),2.13(d,J=6.1Hz,1H),2.07–1.99(m,2H),1.41 (d,J=1.7Hz,2H),1.37(d,J=1.6Hz,2H),1.36(s,2H),1.34(s,2H),1.25(s,3H),1.22(d,J=5.6Hz,3H),1.20(d,J=2.7Hz,3H),1.11(s,3H).13C NMR (126MHz, CDCl3) δ181.67,172.07,171.71,170.12,169.46,146.94,146. 03,134.66,134.35,133.80,132.76,132.29,129.20,127.18,124.94,124.3 6,120.56,52.56,49.04,45.56,38.91,38.20,37.50,36.60,34.37,33.11,31.52,30.35,29.44,27.09,25.28,24.06,23.41,21.49,19.96,18.73,16.59.
[0068] Final product T3 (white powder, 32.5%): ESI-MS m / z 663.35 [M+Na]+.1H NMR(500MHz,Chloroform-d)δ9.53–9.18(m,1H),9.05–8.89(m,1H),7.84–7.6 9(m,1H),7.59(q,J=7.2Hz,1H),7.45–7.30(m,1H),7.22–7.03(m,1H),6.98(d t,J=7.0,3.3Hz,1H),6.88–6.62(m,1H),6.23–5.95(m,1H),5.02(ddt,J=10.3 ,7.4,5.1Hz,1H),4.40–4.27(m,2H),3.20(dh,J=28.9,7.3Hz,2H),2.84–2.77 (m,2H),2.66(dtd,J=29.6,17.6,15.3,7.2Hz,2H),2.37(d,J=7.4Hz,2H),2.2 7(d,J=15.2Hz,2H),2.12–1.99(m,2H),1.66(d,J=7.6Hz,2H),1.53(q,J=6.8H z,2H),1.48–1.43(m,2H),1.40(d,J=9.7Hz,1H),1.25–1.21(m,3H),1.20(s,3 H),1.19(s,3H),1.18–1.15(m,3H),0.98–0.89(m,2H),0.86–0.81(m,2H).13C NMR (126MHz, CDCl3) δ179.00,172.36,172.07,170.54,169.35,147.77,145.89, 134.56,133.43,132.51,129.60,129.09,126.99,126.45,124.18,124.10,120. 57,53.12,48.18,45.56,44.16,39.58,38.05,37.29,37.05,36.62,35.72,33.54,31.17,30.05,29.35,28.73,27.15,25.41,24.10,23.20,21.22,18.73,16.63.
[0069] Final product T4 (white powder, 38.7%): ESI-MS m / z 677.37 [M+Na] + . 1H NMR(500MHz,Chloroform-d)δ9.35–9.12(m,1H),8.81(d,J=34.7Hz,1H),7.84–7.69(m,1H),7.61(t,J=7.9Hz,1H),7.38(dt,J=15.7,7.8Hz,1H),7.13(dd,J=8.2,4.4Hz,1H),6.98(dd,J=8.2,2.0Hz,1H),6.84(dd,J=4.5,2.0Hz,1H),6.08–5.95(m,1H),5.03(dt,J=13.6,4.3Hz,1H),4.43–4.30(m,2H),3.18(tq,J=20.0,6.6Hz,2H),2.85–2.78(m,2H),2.73–2.58(m,2H),2.37(t,J=7.4Hz,2H),2.29–2.18(m,2H),2.06(ddd,J=12.8,7.8,2.3Hz,2H),2.00–1.93(m,2H),1.88–1.81(m,1H),1.69(d,J=7.1Hz,2H),1.44(d,J=6.8Hz,2H),1.31–1.28(m,2H),1.27–1.25(m,2H),1.22(d,J=4.5Hz,3H),1.20(d,J=5.1Hz,3H),1.19(d,J=5.3Hz,3H),1.18–1.12(m,3H),0.99–0.93(m,1H),0.86(tq,J=10.5,5.4,4.0Hz,2H). 13 C NMR(126MHz,CDCl3)δ185.75,178.74,173.03,170.93,169.13,147.77,147.06,145.85,134.59,133.43,132.27,132.05,128.36,126.99,124.18,123.73,120.31,60.53,53.56,51.41,47.31,45.87,44.37,39.59,37.29,37.11,33.56,31.39,30.08,29.82,29.32,26.33,25.30,25.14,24.10,21.18,16.60,13.95.
[0070] Final product T5 (white powder, 36.3%): ESI-MS m / z 691.38 [M+Na]+.1H NMR(500MHz,Chloroform-d)δ9.16(d,J=13.2Hz,1H),9.01(d,J=21.3Hz,1H),7. 71(t,J=8.2Hz,1H),7.63(dd,J=7.5,3.9Hz,1H),7.45–7.34(m,1H),7.14(d,J=8. 3Hz,1H),6.99(dd,J=8.2,2.0Hz,1H),6.85(t,J=2.4Hz,1H),6.05–5.83(m,1H), 5.03(dd,J=13.2,5.6Hz,1H),4.46–4.30(m,2H),3.17(p,J=6.7Hz,2H),2.87–2.7 9(m,2H),2.74–2.61(m,2H),2.36(t,J=7.3Hz,2H),2.32–2.17(m,2H),2.13–2.0 7(m,2H),2.06–1.99(m,2H),1.76(dd,J=10.4,8.0Hz,2H),1.69–1.65(m,2H),1.6 3–1.51(m,2H),1.48–1.44(m,2H),1.42(d,J=6.8Hz,2H),1.24(s,3H),1.21(s,3H ),1.20(s,3H),1.17(d,J=17.0Hz,3H),0.99–0.88(m,2H),0.87–0.79(m,2H).13C NMR (126MHz, CDCl3) δ178.83,173.56,171.70,170.23,169.26,149.71,147.59,1 45.81,134.90,133.35,132.55,129.50,128.98,126.90,125.58,124.10,120.20, 67.79,54.78,51.87,47.69,45.49,39.89,37.99,37.31,37.03,35.95,33.45,31.44,29.99,29.52,28.25,26.15,25.50,25.22,23.99,23.17,21.17,18.71,15.87.
[0071] Final product T6 (white powder, 35.9%): ESI-MS m / z 705.40 [M+Na] + . 1H NMR(500MHz,Chloroform-d)δ9.24(s,1H),9.02(d,J=3.3Hz,1H),7.70(dd,J=11.8,8.2H z,1H),7.62(t,J=7.3Hz,1H),7.42–7.34(m,1H),7.13(dd,J=8.3,3.5Hz,1H),6.98(dd,J =8.2,2.0Hz,1H),6.84(d,J=2.0Hz,1H),5.99(t,J=5.8Hz,2H),5.02(td,J=9.1,4.6Hz,1 H),4.35(dd,J=20.2,5.4Hz,2H),4.11(q,J=7.1Hz,1H),3.17(dt,J=12.8,5.7Hz,2H),2. 84–2.80(m,2H),2.75–2.62(m,2H),2.38(d,J=7.5Hz,2H),2.29–2.19(m,2H),2.08(dt,J =12.5,2.1Hz,2H),1.73(d,J=4.9Hz,2H),1.65(s,2H),1.55–1.48(m,2H),1.45(dd,J=6. 5,2.4Hz,2H),1.41–1.38(m,2H),1.25(d,J=7.2Hz,3H),1.23–1.23(m,3H),1.21(s,3H), 1.19(d,J=2.0Hz,3H),0.95(dt,J=9.3,2.8Hz,2H),0.94–0.86(m,2H),0.86–0.80(m,2H). 13 CNMR(126MHz, CDCl3)δ178.83,172.92,171.89,170.39,169.87,148.07,145.10,13 5.94,133.47,132.61,129.59,129.07,126.98,125.49,125.02,123.62,121.71,67. 18,61.49,51.90,47.35,45.59,39.73,38.63,38.02,37.36,36.73,33.15,31.52,30.67,29.61,28.98,28.66,25.53,25.31,24.09,21.22,18.79,17.04,14.30,12.40.
[0072] Example 2
[0073] (1) Preparation of intermediates w2-6 and 8
[0074] The structural formula of intermediate w2(n=1) / w3(n=2) / w4(n=3) / w5(n=4) / w6(n=5) / w8(n=7) is The specific synthesis method is as follows:
[0075] Fluorothalidamide (2 g, 7.241 mmol) was dissolved in 20 mL DMF and stirred to dissolve, then DIEA (1.872 mL, 14.481 mmol) and N-Boc-1,2-ethylenediamine (1.39 mL, 8.689 mmol) were added and the temperature was raised to 90°C and refluxed for 12 h. After the reaction was completed, ice water was used to quench the reaction, and ethyl acetate was used for extraction. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (PE: EA = 1: 1) to obtain w2 (yellow transparent oil, 1.3533 g, yield 60%)
[0076] Fluorothalidamide (2 g, 7.241 mmol) was dissolved in 20 mL DMF and stirred to dissolve, then DIEA (1.872 mL, 14.481 mmol) and N-Boc-1,3-propylenediamine (1.49 mL, 8.689 mmol) were added and the temperature was raised to 90 ° C and refluxed for 12 h. After the reaction was completed, it was quenched with ice water and extracted with ethyl acetate. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (PE: EA = 1: 1) to obtain w3 (yellow transparent oil, 1.4209 g, yield 63%)
[0077] Fluorothalidamide (2 g, 7.241 mmol) was dissolved in 20 mL DMF and stirred to dissolve, then DIEA (1.872 mL, 14.481 mmol) and N-Boc-1,4-butanediamine (2 mL, 8.689 mmol) were added and the temperature was raised to 90 ° C and refluxed for 12 h. After the reaction was completed, it was quenched with ice water and extracted with ethyl acetate. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (PE: EA = 1: 1) to obtain w4 (yellow transparent oil, 1.53374 g, yield 68%)
[0078] Fluorothalidamide (2 g, 7.241 mmol) was dissolved in 20 mL DMF and stirred to dissolve, then DIEA (1.872 mL, 14.481 mmol) and N-Boc-1,5-pentanediamine (1.59 mL, 8.689 mmol) were added and the temperature was raised to 90°C and refluxed for 12 h. After the reaction was completed, ice water was used to quench the reaction, and ethyl acetate was used to extract the reaction. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (PE: EA = 1: 1) to obtain w5 (yellow transparent oil, 1.5111 g, yield 67%)
[0079] Fluorothalidamide (2 g, 7.241 mmol) was dissolved in 20 mL DMF and stirred to dissolve, then DIEA (1.872 mL, 14.481 mmol) and N-Boc-1,6-hexanediamine (1.69 mL, 8.689 mmol) were added and the temperature was raised to 90°C and refluxed for 12 h. After the reaction was completed, it was quenched with ice water and extracted with ethyl acetate. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (PE: EA = 1: 1) to obtain w6 (yellow transparent oil, 1.5788 g, yield 70%).
[0080] Fluorothalidamide (2 g, 7.241 mmol) was dissolved in 20 mL DMF and stirred to dissolve, then DIEA (1.872 mL, 14.481 mmol) and N-Boc-1,8-octanediamine (1.79 mL, 8.689 mmol) were added and the temperature was raised to 90°C and refluxed for 12 h. After the reaction was completed, ice water was used to quench the reaction, and ethyl acetate was used for extraction. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (PE: EA = 1: 1) to obtain w8 (yellow transparent oil, 1.5113 g, yield 67%).
[0081] (2) Preparation of intermediate a1 (same as Example 1)
[0082] (3) Preparation of final product T7-12
[0083] The intermediate a1 (1 eq), w2 / w3 / w4 / w5 / w6 / w8 (2 eq), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCl) (2 eq), and 4-dimethylaminopyridine (DMAP) (1 eq) were dissolved in DCM (5 ML) in sequence. The reaction was stirred at room temperature for 5 to 8 hours, extracted with DCM, and the organic phase was washed with 5% NaHCO3 solution and saturated sodium chloride, and dried over anhydrous Na2SO4. The solid was removed by filtration, and the solvent was evaporated under reduced pressure to obtain a crude product, which was then purified by column chromatography (PE-EA=10:1 to 1:1, v / v) to obtain the final product T7 / 8 / 9 / 10 / 11 / 12, whose NMR data are as follows:
[0084] Final product T7 (fluorescent yellow powder, 44.7%): ESI-MS m / z 621.30 [M+Na]+. 1H NMR (500MHz, Chloroform-d) δ8.81 (d, J=3.7 Hz, 1H), 7.50–7.47 (m, 1H), 7.13 (d, J=8.2 Hz, 1H), 7.08 (d, J=7.0 Hz, 1H), 7.01 (d, J=8.6 Hz, 1H), 6.97 (d, J=8.1 Hz, 1H), 6.82 (s, 1H), 6.43 (s, 1H), 6.40 (q, J=3.4 Hz, 1H), 4.91 (dd, J=9.5, 2.6 Hz, 1H), 3.49–3.46 (m, 2H),3.43(d,J=9.2Hz,2H),2.78(d,J=6.7Hz,2H),2.77(s,2H),2.70(s,1H),2.28(d,J=13.1Hz,1H),2.11–2.05(m,2H),1.74(d ,J=9.2Hz,2H),1.48(d,J=13.3Hz,2H),1.22(s,3H),1.19(s,3H),1.18(s,3H),0.95(d,J=9.4Hz,1H),0.84(t,J=6.2Hz,2H).13C NMR (126MHz, CDCl3) δ179.49,172.22,170.56,168.84,167.69,147.01,1 46.95,145.79,136.42,134.66,132.50,126.92,124.49,123.96,117.10 ,111.95,110.21,50.80,48.98,47.45,45.48,42.12,39.46,38.01,37.2 8,37.10,33.51,31.45,29.94,25.24,24.07,22.82,21.21,18.77,16.54.
[0085] Final product T8 (fluorescent yellow powder, 45.2%): ESI-MS m / z 635.32 [M+Na] + . 1 H NMR(500MHz,Chloroform-d)δ8.80(d,J=6.9Hz,1H),7.49–7.45(m,1H),7.14(d,J =8.1Hz,1H),7.06(dd,J=7.1,2.8Hz,1H),6.98(dd,J=8.1,2.0Hz,1H),6.86(d,J=8 .5Hz,1H),6.84(d,J=2.0Hz,1H),6.38(q,J=5.8Hz,1H),6.27–6.13(m,1H),4.93– 4.88(m,1H),3.38–3.34(m,2H),3.30(d,J=6.4Hz,2H),2.83(dd,J=8.1,3.5Hz,2H) ,2.80–2.78(m,1H),2.71(q,J=3.8Hz,1H),2.28(dd,J=13.7,3.5Hz,1H),2.10–2. 04(m,2H),1.83(t,J=6.7Hz,2H),1.77–1.73(m,2H),1.67(dd,J=9.3,3.5Hz,1H),1 .52(qd,J=9.1,8.6,3.2Hz,2H),1.46(d,J=7.3Hz,1H),1.23(s,3H),1.20(s,3H), 1.19(d,J=1.4Hz,3H),1.15(s,3H),0.98–0.94(m,1H),0.85(h,J=5.6,4.8Hz,2H). 13 C NMR (126MHz, CDCl3) δ178.98,171.73,169.54,168.81,167.69,147.04,1 46.77,145.78,136.27,134.62,132.97,127.37,124.11,124.00,116.67 ,111.64,110.52,48.95,47.34,45.47,40.18,38.02,37.36,37.13,33.5 0,31.45,30.01,29.53,25.26,24.07,24.05,22.81,21.24,18.80,16.57.
[0086] Final product T9 (fluorescent yellow powder, 43.3%): ESI-MS m / z 649.34 [M+Na] + . 1H NMR(500MHz,Chloroform-d)δ8.71(s,1H),7.48–7.44(m,1H),7.14(d,J=8.2Hz, 1H),7.06(d,J=7.1Hz,1H),6.98(dd,J=8.3,2.0Hz,1H),6.87(d,J=8.6Hz,1H),6. 84(d,J=2.0Hz,1H),6.24(t,J=5.8Hz,1H),5.99(t,J=5.8Hz,1H),4.91(dd,J=12. 1,5.4Hz,1H),3.30(d,J=6.6Hz,2H),3.27(d,J=6.6Hz,2H),2.83(dd,J=8.5,3.6H z,2H),2.81–2.77(m,1H),2.77–2.70(m,2H),2.28(dd,J=13.4,3.4Hz,1H),2.12 –2.08(m,2H),1.76(dd,J=9.1,3.8Hz,2H),1.73–1.72(m,1H),1.69–1.65(m,2H), 1.64(d,J=7.2Hz,2H),1.60(dd,J=8.0,5.3Hz,2H),1.52(d,J=9.9Hz,1H),1.23(s ,3H),1.20(s,3H),1.19(s,3H),1.15(s,3H),0.96(d,J=8.6Hz,1H),0.85(s,1H). 13 C NMR (126MHz, CDCl3) δ178.66,172.68,169.62,168.77,167.70,147.05,146. 90,145.77,136.26,134.65,132.51,126.93,124.12,123.98,116.78,111.5 8,109.97,48.93,47.30,45.52,42.23,39.31,38.02,37.38,37.12,33.50,31.46,30.02,27.24,26.63,25.28,24.06,24.05,22.83,21.20,18.80,16.57.
[0087] Final product T10 (fluorescent yellow powder, 48.2%): ESI-MS m / z 663.35 [M+Na] + . 1H NMR(500MHz,Chloroform-d)δ8.54(s,1H),7.50–7.46(m,1H),7.15(d,J=8.1Hz, 1H),7.07(d,J=7.1Hz,1H),6.98(dd,J=8.1,2.0Hz,1H),6.87(s,1H),6.86–6.84( m,1H),6.23(t,J=5.6Hz,1H),5.87(t,J=5.7Hz,1H),4.90(dd,J=12.3,5.3Hz,1H ),3.27(d,J=6.5Hz,2H),3.24(d,J=6.7Hz,2H),2.88–2.84(m,2H),2.82–2.78(m, 1H),2.77–2.69(m,2H),2.29(dd,J=13.3,3.0Hz,1H),2.10(dq,J=12.2,3.3Hz,2 H),1.75(d,J=5.3Hz,2H),1.73–1.71(m,1H),1.69(d,J=7.3Hz,2H),1.55(d,J=7. 8Hz,2H),1.52(d,J=2.8Hz,2H),1.43(d,J=7.1Hz,2H),1.24(s,3H),1.21(s,3H) ,1.20(d,J=4.7Hz,3H),1.19–1.13(m,3H),0.98–0.94(m,1H),0.87–0.83(m,2H). 13 C NMR (126MHz, CDCl3) δ178.55,171.40,169.61,168.64,167.74,147.08,147.0 1,145.82,136.25,134.67,132.96,128.26,124.16,124.01,116.76,111.55,1 09.98,50.85,48.96,47.32,45.63,42.56,39.64,38.06,37.38,37.15,33.53,31.50,30.08,29.50,28.94,25.30,24.33,24.07,22.88,21.20,18.84,17.34.
[0088] Final product T11 (fluorescent yellow powder, 47.3%): ESI-MS m / z 677.37 [M+Na] + . 1H NMR(500MHz,Chloroform-d)δ8.52(s,1H),7.49–7.45(m,1H),7.15(d,J=8.2Hz, 1H),7.08(s,1H),6.98(dd,J=8.2,2.1Hz,1H),6.87(s,1H),6.86–6.84(m,1H),6. 23(t,J=5.7Hz,1H),5.82(d,J=5.5Hz,1H),4.91(dd,J=8.0,4.3Hz,1H),3.26(dd ,J=7.4,2.5Hz,2H),3.25–3.23(m,2H),2.87(d,J=4.3Hz,1H),2.82–2.76(m,2H), 2.76–2.65(m,2H),2.32–2.26(m,1H),2.12–2.08(m,2H),1.76(d,J=9.8Hz,2H), 1.73(q,J=2.3Hz,1H),1.65(d,J=7.4Hz,2H),1.58–1.53(m,2H),1.50(d,J=3.5Hz ,2H),1.43(t,J=6.7Hz,2H),1.38–1.34(m,2H),1.25(d,J=3.1Hz,3H),1.21(s,3 H),1.20(s,3H),1.19(s,3H),0.97(d,J=8.5Hz,1H),0.85(dd,J=6.9,5.4Hz,2H). 13 C NMR (126MHz, CDCl3) δ178.45,171.40,169.61,168.65,167.73,147.10,14 7.05,145.79,136.22,134.69,132.57,126.96,124.15,123.99,116.74,11 1.49,109.95,48.95,47.30,45.62,39.71,38.07,37.40,37.15,33.53,31. 49,30.07,29.66,29.22,26.69,25.31,24.07,22.88,21.19,18.84,16.62.
[0089] Final product T12 (fluorescent yellow powder, 45.2%): ESI-MS m / z 733.43 [M+Na] + . 11H NMR (500 MHz, Chloroform-d) δ 8.40 (d, J = 5.4 Hz, 1H), 7.48 (dd, J = 8.6, 7.0 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 7.07 (d, J = 7.1 Hz, 1H), 6.99 (dd, J = 8.2, 2.0 Hz, 1H), 6.88 (s, 1H), 6.86–6.84 (m, 1H), 6.23 (t, J = 5.6 Hz, 1H), 5.78 (t, J = 5.7 Hz, 1H), 4.91 (ddd, J = 12.3, 5.3, 1.7 Hz, 1H), 3.26 (d, J = 6.6 Hz, 2H), 3.24–3.21 (m, 2H), 2.89–2.84 (m, 2H), 2.84–2.79 (m, 1H), 2.79–2.67 (m, 2H), 2.33–2.23 (m, 1H), 2.11 (ddd, J = 12.3, 5.5, 2.3 Hz, 2H), 1.89 (ddd, J = 15.7, 5.8, 2.4 Hz, 1H), 1.79–1.75 (m, 2H), 1.75–1.69 (m, 2H), 1.66 (q, J = 7.3 Hz, 2H), 1.59 (d, J = 32.9 Hz, 2H), 1.54 (d, J = 2.4 Hz, 1H), 1.51–1.48 (m, 2H), 1.46 (q, J = 3.0 Hz, 2H), 1.39 (d, J = 6.9 Hz, 2H), 1.35 (s, 1H), 1.32 (d, J = 3.1 Hz, 3H), 1.25 (s, 3H), 1.21 (d, J = 1.2 Hz, 3H), 1.20 (s, 3H), 1.17 (s, 1H), 1.00–0.95 (m, 1H), 0.91–0.84 (m, 2H), 0.84–0.72 (m, 1H). 13 13C NMR (126 MHz, CDCl3) δ 178.38, 171.28, 169.62, 168.56, 167.75, 147.13, 147.11, 145.37, 136.72, 134.74, 132.59, 127.55, 124.18, 122.56, 116.76, 112.06, 109.93, 53.56, 48.96, 47.30, 45.66, 42.15, 40.55, 39.88, 39.82, 38.09, 37.41, 37.17, 33.55, 31.52, 30.10, 29.73, 29.25, 29.21, 26.92, 25.34, 23.69, 22.92, 21.18, 18.87, 16.64.
[0090] Example 3
[0091] (1) Preparation of intermediates p1-p3
[0092] The structural formula of the intermediate p1(n=0) / p2(n=1) / p(n=2)3 is
[0093]
[0094] Synthesis of intermediate p1: Fluorothalidamide (100 mg, 0.362 mmol, 1 eq) was dissolved in 3 mL DMF and stirred to dissolve, then DIEA (120 μL, 0.742 mmol, 2 eq) and N-Boc-2,2'-(ethylene monooxy)diethylamine (129 μL, 0.543 mmol, 1.5 eq) were added and the temperature was raised to 90°C and refluxed for 12 h. After the reaction was completed, ice water was used to quench the reaction, and ethyl acetate was used for extraction. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate and concentrated to obtain intermediate p2 (yellow oil, 440 mg, 30%)
[0095] Synthesis of intermediate p2: Fluorothalidamide (100 mg, 0.362 mmol, 1 eq) was dissolved in 3 mL DMF and stirred to dissolve, then DIEA (120 μL, 0.742 mmol, 2 eq) and N-Boc-2,2'-(ethylenedioxy)diethylamine (129 μL, 0.543 mmol, 1.5 eq) were added and the temperature was raised to 90°C and refluxed for 12 h. After the reaction was completed, ice water was used to quench the reaction, and ethyl acetate was used for extraction. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate and concentrated to obtain intermediate p2 (yellow oil, 440 mg, 30%)
[0096] Synthesis of intermediate p3: Fluorothalidamide (2 g, 7.241 mmol, 1 eq) was dissolved in 20 mL DMF and stirred to dissolve, then DIEA (1.872 mL, 14.481 mmol, 2 eq) and N-Boc-2,2'-(ethylenetrioxy)diethylamine (2 mL, 8.689 mmol, 1.2 eq) were added and the temperature was raised to 90°C and refluxed for 12 h. After the reaction was completed, ice water was used to quench the reaction, and ethyl acetate was used for extraction. The combined organic phase was washed with saturated NaHCO3 and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (PE: EA = 1: 1) to obtain intermediate p3 (yellow transparent oil, 228.6 mg, yield 30%)
[0097] (2) Preparation of intermediate a1 (same as Example 1)
[0098] (3) Preparation of final product T13-15
[0099] The intermediate a1 (1 eq) and DIPEA (3 eq) were dissolved in 1 mL of dry DMF solution, stirred at room temperature for 5 min, HATU (1.5 eq) was added, and the reaction was monitored by TLC for about 0.5 h. Then, p1 / 2 / 33 (2 eq) was added and stirred at room temperature. TLC was used to track the reaction, and the reaction was completed in about 12 h. Crushed ice was added to the reaction solution to quench the reaction, and ethyl acetate was extracted 3 times. The organic layers were combined, washed with saturated ammonium chloride solution and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and subjected to PTLC (dichloromethane: methanol = 15:1) to obtain the final product T13 / 14 / 15, whose NMR data are as follows:
[0100] Final product T13 (fluorescent yellow powder, 42.1%): ESI-MS m / z 665.33 [M+Na]+. 1H NMR (500MHz, Chloroform-d) δ8.64 (d, J=5.4 Hz, 1H), 7.51–7.47 (m, 1H), 7.15–7.11 (m, 1H), 7.11–7.08 (m, 1H), 6.97 (dt, J=8.2, 2.0 Hz, 1H), 6.91 (d, J=8.5 Hz, 1H), 6.82 (d, J=2.4Hz,1H),6.50(t,J=5.1Hz,1H),6.31(dq,J=11.5,5.3,4.6Hz,1H),4.91(qd,J=7 .0,6.3,2.1Hz,1H),3.69(t,J=5.1Hz,2H),3.57(t,J=4.9Hz,2H),3.46(s,2H),3.44(s ,1H),2.85(ddd,J=17.6,9.0,4.1Hz,2H),2.79(dd,J=7.7,4.3Hz,2H),2.26(dd,J=13 .2,3.5Hz,1H),2.14–2.06(m,2H),2.00(d,J=6.2Hz,1H),1.79–1.72(m,2H),1.70(dd ,J=10.8,4.9Hz,2H),1.49–1.44(m,2H),1.20(s,3H),1.19(s,3H),1.18(d,J=1.9Hz, 3H),1.15(d,J=25.7Hz,3H),0.96–0.92(m,1H),0.83(dtd,J=9.0,6.3,3.5Hz,2H).13C NMR (126MHz, CDCl3) δ178.81,171.91,169.51,168.62,166.49,148.13,146. 90,144.88,136.25,134.70,132.56,126.90,124.17,123.96,116.84,112.5 2,110.40,70.09,67.82,50.82,49.00,47.28,45.47,41.83,39.64,38.00,37.12,37.04,33.51,31.18,30.11,25.30,24.06,22.84,21.13,18.81,15.54.
[0101] Final product T14 (fluorescent yellow powder, 46.7%): ESI-MS m / z 709.36 [M+Na]+. 1H NMR (500 MHz, Chloroform-d) δ8.93–8.79 (m, 1H), 7.53–7.49 (m, 1H), 7.20–7.12 (m, 1H), 7.11 (s, 1H), 7.00 (dd, J=8.3, 2.0 Hz, 1H), 6.91 (t, J=9.3 Hz, 1H), 6.86 (s, 1H), 6.51 (t ,J=5.4Hz,1H),6.33(dt,J=17.1,5.6Hz,1H),4.94–4.89(m,1H),3.77–3.70(m,2H),3. 67(s,2H),3.60(q,J=4.8,4.3Hz,2H),3.50–3.47(m,2H),3.44(d,J=5.5Hz,1H),2.86(d t,J=10.5,3.8Hz,2H),2.78–2.68(m,2H),2.29(dd,J=13.2,3.9Hz,1H),2.12(ddt,J=1 3.0,10.4,2.7Hz,2H),2.06–2.00(m,1H),1.83–1.76(m,2H),1.73(ddd,J=19.7,9.0,6 .5Hz,2H),1.69(s,1H),1.57–1.51(m,2H),1.50–1.47(m,1H),1.28–1.24(m,3H),1.23 (s,3H),1.21(s,3H),1.19(d,J=14.8Hz,3H),0.98–0.95(m,1H),0.89–0.82(m,2H).13C NMR (126MHz, CDCl3) δ177.26,173.00,169.96,168.30,167.00,148.13,146. 83,144.74,136.17,134.78,132.64,126.93,124.18,123.20,117.34,112.9 3,110.45,70.80,70.18,70.05,69.36,53.55,48.97,47.29,45.57,42.37,39.56,38.03,37.06,33.52,31.48,30.10,25.32,24.08,22.95,18.82,17.20.
[0102] Final product T15 (fluorescent yellow powder, 45.3%): ESI-MS m / z 753.38 [M+Na] + . 1H NMR(500MHz,Chloroform-d)δ8.90(d,J=6.2Hz,1H),7.46(ddd,J=8.7,7.2,2.6Hz,1H),7 .13(d,J=8.2Hz,1H),7.07(d,J=7.1Hz,1H),6.96(dd,J=8.2,2.0Hz,1H),6.89(dd,J=8.6, 4.0Hz,1H),6.83(d,J=2.0Hz,1H),6.47(t,J=5.6Hz,1H),6.40–6.30(m,1H),4.89(dd,J=1 2.0,5.5Hz,1H),3.70(dd,J=10.0,5.2Hz,2H),3.65(s,2H),3.64(d,J=3.9Hz,2H),3.63(s ,1H),3.61–3.60(m,2H),3.53(dt,J=5.3,2.3Hz,2H),3.45(d,J=5.6Hz,2H),3.43(s,2H), 2.87–2.81(m,2H),2.80–2.72(m,2H),2.30–2.23(m,2H),2.13–2.04(m,2H),1.72(dd,J=1 0.9,3.4Hz,2H),1.56–1.50(m,2H),1.48–1.43(m,2H),1.23(d,J=3.1Hz,3H),1.19(s,3H) ,1.18(s,3H),1.18–1.14(m,3H),0.95(dd,J=6.4,3.8Hz,1H),0.83(q,J=5.0,3.7Hz,2H). 13 C NMR (126MHz, CDCl3) δ178.71,171.57,169.81,168.72,167.20,147.07,146.82, 145.02,136.09,134.73,132.56,126.89,124.13,123.89,116.80,111.71,109. 61,70.79,70.58,70.54,70.19,69.97,69.51,48.51,47.25,44.73,42.40,39.46,37.99,37.10,33.47,31.47,30.06,25.30,23.48,22.82,21.09,18.79,16.49.
[0103] Example 4 In vitro antitumor activity test of dehydroabietic acid PROTACs (IC 50 )
[0104] The dehydroabietic acid PROTACs prepared in Examples 1 to 3 of the present invention were tested for their ability to inhibit tumor cell proliferation, and the test method used the conventional CCK-8 method. When the tumor cells (MCF-7 cells (human breast cancer cells)) grew to 80% to 90% of the culture dish, the cells were digested from the culture dish, resuspended in fresh DMEM / 1640 complete medium after centrifugation, counted under a microscope, and then the cell suspension was diluted to 50 cells / μL. A circle of sterile PBS was spread on the outermost periphery of the 96-well plate, 100 μL per well, and 100 μL of diluted cell suspension was spread on each well of the remaining wells, and cultured in a 37°C, 5% CO2 incubator. After 24 hours, the medium in the 96-well plate was removed, and the drug was diluted with fresh complete medium in a certain concentration gradient, and then added to the 96-well plate in sequence. After 48 hours, the medium containing the drug was removed, and CCK-8 liquid diluted with the medium (100 μL medium + 10 μL CCK-8) was added, and the plate was placed in a 37°C, 5% CO2 incubator for 30 to 40 minutes. The absorbance was detected at OD 450 on a microplate reader, and the inhibition rate was calculated based on the absorbance at OD 450. The data obtained were used to calculate the half-maximal inhibition concentration IC50 using SPSS software.
[0105] The calculation formula is as follows:
[0106] Inhibition rate = [(Ac-As) / (Ac-Ab)] × 100%
[0107] As: absorbance of experimental wells (containing cells, culture medium, CCK-8 solution, and drug solution);
[0108] Ac: absorbance of control well (containing cells, culture medium, CCK-8 solution, but no drug);
[0109] Ab: absorbance of blank well (containing culture medium and CCK-8 solution, but not cells or drugs).
[0110] Experimental results: To further evaluate the in vitro antitumor activity of the target compound, MCF-7, Hela and A549 cells (human lung cancer cells) were selected as test tumor strains, and T was used as the control group. The test results are shown in Table 1. Overall, the antitumor activity of dehydroabietic acid PROTACs is better than that of dehydroabietic acid derivatives. Combined with IC50 and compound structure, B13 was selected as the dosing group for further proteomic research and analysis.
[0111] Table 1 In vitro antitumor activity (IC50) of T and T1 to T15
[0112]
[0113]
[0114] Example 5 Proteomic Analysis of Dehydroabietic Acid PROTACs
[0115] In this embodiment, a total of 9 cell samples were set up, divided into 3 groups, namely PROTACs group (drug group / T-PROTAC), atNP group (control group / T) and blank group (con), and the biological replicates corresponding to each group were 3 cases. Three groups of data were compared, drug group VS control group, drug group VS blank group and control group VS blank group. The obtained data were searched and analyzed using Proteome Discoverer software (PD) (version 2.4.0.305, Thermo Fisher Scientific) and the built-in Sequest HT search engine.
[0116] Experimental results: Based on LC-MS quantitative analysis of proteins, a total of 6105 proteins and 41392 polypeptides were identified in this example. The distribution of differential proteins is as follows Figure 1 A, Con VS T-PROTAC differential protein subcellular localization analysis Figure 1 B, Analysis of differential protein subcellular localization of T-PROTACs VS T Figure 1 C, Analysis of differential subcellular localization of proteins in con vs T Figure 1 D. Since the mechanism of action of PROTACs small molecules is to directly degrade proteins, this example focuses on the downregulated differential proteins among the total differential proteins. The top 20 downregulated differential proteins of T-PROTAC VS T are as follows: Figure 2 The top 20 down-regulated differentially expressed proteins of T-PROTAC VS con are as follows: Figure 3 , (based on the screening principle) screened out the common differential proteins in the two groups, combined with some differential proteins in T VS con ( Figure 4 ), EIF1, TMBIM6, and FANCA were initially identified as potential target proteins for the anti-tumor effects of dehydroabietic acid. TMBIM6 is an inhibitor of apoptosis
[158] and can perform signal transduction by regulating the unfolded protein response. At the same time, TMBIM6 also regulates calcium homeostasis in the endoplasmic reticulum by acting as a calcium leak channel. In addition, further studies have shown that TMBIM6 has also been used to study several pathways related to apoptosis. First, it can directly inhibit the IRE1α signaling pathway and downstream XBP1 mRNA splicing by competing with BAX / BAK for the IRE1α binding site. Second, because TMBIM6 is located on the ER membrane, it is involved in the [Ca] 2+ ]. Cells overexpressing BI-1 have a negative effect on the regulation of resting ER Ca 2+ Low levels of ER Ca 2+Leakage is higher, while downregulation of TMBIM6 results in increased mitochondrial Ca 2+ Increased uptake of Ca 2+ Finally, TMBIM6 can prevent the accumulation of ROS under ER stress conditions by interacting with MMO members NPR and CYP2E1, and TMBIM6 can also promote antioxidant responses through NRF2 and heme oxygenase 1 (HO-1), thereby counteracting the damage caused by ROS to cells.
[0117] Example 6 Molecular docking results of dehydroabietic acid and potential target TMBIM6
[0118] The docking simulation of dehydroabietic acid and TMBIM6 was carried out as follows:
[0119] (1) Prepare the software running environment: First, create a folder named autodock.vina and copy the vina.exe program to the folder. Then open AutoDockTools, find set in File-Preferences, and select the autodock vina folder in the startup dictionary. Click make definition to complete the setup. All information will be saved in the folder.
[0120] (2) Prepare the protein: Download the protein from the PDB database, use PyMOL software to remove water molecules and receptor proteins, and save it in PDB format with the file name **.pdb. Then import it into the AutoDock Tools software, select Edit-Hydrogens-Add hydrogen, Edit-ChargesComputeGasteige calculate charge, and Edit-Atoms-AssignAD4type to set the atom type. After completion, output it to the software-specific format .pdbqt, with the file name **.pdbqt.
[0121] (3) Prepare the receptor molecule: Use Chemdraw to draw the molecular structure of the small molecule, then open the Chemdraw3D software, import the small molecule into it, and click CalcμLationMM2-minimize energy in the menu bar to optimize the small molecule structure. After completion, click Save As in File to output it in PDB format, and the file name is small molecule.pdb. Then use read molecμLe in File in the AutoDockTools software to open the small molecule.pdb, and perform Edit-Hydrogens-Add hydrogenation, Ligand-Torsion Tree-DetectRoot to calculate the maximum number of rotatable bonds, and Ligand-TorsionTree-Choose Torsions-Done to set the rotatable bonds. After completion, set it as a ligand and export it in the small molecule.pdbqt special format.
[0122] (4) Molecular docking: Finally, the target and the active ingredient structure are molecularly docked using vina in the pyrx software (https: / / pyrx.sourceforge.io / ). The affinity (kcal / mol) value represents the binding ability of the two. The lower the binding ability, the more stable the binding between the ligand and the receptor.
[0123] (5) Result processing: Use AutoDockTools to open resμLt.pdbqt and export it as a pdb format file, and then use PyMOL to open it. Import resμLt.pdb into PyMOL, select the optimal model from the 9 small molecule conformations, and analyze the interaction between the compound and the protein. It is generally believed that a docking energy value less than -4.25 kcal / mol indicates a certain binding activity between the two, less than -5.0 kcal / mol indicates a good binding activity, and less than -7.0 kcal / mol indicates a strong binding activity.
[0124] Experimental results: The docking results of TMBIM6 protein and small molecules are as follows Figure 5 As shown: The protein small molecule and the receptor binding pocket show a high degree of fit, with a binding energy of -8.0 kcal / mol, and have the potential to bind under natural conditions. In addition, the TMBIM6 molecule forms a hydrogen bond with the amino acid residue PHE-39 in the protein and the small molecule ligand. In summary, the TMBIM6 protein has the potential to form more interactions with molecules.
[0125] Example 7 Degradation efficiency test of dehydroabietic acid PROTACS for potential target protein TMBIM6
[0126] The dehydroabietic acid PROTAC compound T15 prepared in Example 3 of the present invention was tested for its potential target protein degradation efficiency. The test method adopted the conventional WB method. Based on the existing in vitro anti-tumor test data (IC 50 ), and further tested the degradation efficiency of the potential target protein TMBIM6 by dehydroabietic acid PROTAC. Different concentrations of T15 were used to act on A549 cells, with T as the control group, to study the protein degradation efficiency at different concentrations and explore whether the degradation of TMBIM6 is dependent on the concentration of T15.
[0127] Experimental results: The degradation of TMBIM6 is dependent on the concentration of T15 ( Figure 6 , 7 ), which showed better degradation efficiency than T at 50 μM.
[0128] The above description is only a preferred embodiment of the present invention, and therefore cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the specification should still fall within the scope of the present invention.
Claims
1. A dehydroabietic acid PROTACs, Features: Its structural formula is in, E3 ligase is lenalidomide or pomalidomide, Linker is a fatty chain or a PEG chain. The fatty chain is -NH-(CH 2 )-NH-(CH 2 ) 1 -CH 2 -CH 2 -NH-CO- or -NH-(CH 2 ) 2 -CH 2 -NH-CO-, the PEG chain is -(O-CH 2 -CH 2 ) 3 -CH 2 CO-COOH,n 1 is a natural number from 2 to 7, n 2 is a natural number from 1 to 7, n 3 A natural number from 1 to 3.
2. A dehydroabietic acid PROTACs according to claim 1, Features: Its structural formula is selected from at least one of the following:
3. The method for preparing the dehydroabietic acid PROTACs according to claim 1 or 2, Features: The reaction route is:
4. Use of the dehydroabietic acid PROTACs or pharmacologically or physiologically acceptable salts thereof according to claim 1 or 2 in the preparation of a cancer therapeutic composition.
5. The use according to claim 4, Features: The cancers include breast cancer, uterine cancer and liver cancer.
6. A cancer treatment composition, Features: The active ingredient includes the dehydroabietic acid PROTACs or a pharmacologically or physiologically acceptable salt thereof according to claim 1 or 2.
7. A cancer therapeutic composition according to claim 6, Features: The cancers include breast cancer, uterine cancer and liver cancer.
Citation Information
Patent Citations
Dehydroabietic acid derivative as well as preparation method and application thereof
CN108250043A
C-14 amide substituted dehydroabietic acid derivative as well as preparation method and application thereof
CN115819268A
Protein degradation agent taking abietic acid as hydrophobic group as well as preparation method, pharmaceutical composition and application of protein degradation agent
CN117186013A
